SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3481-3485. Prepublished online as a Blood First Edition Paper on February 2, 2006; DOI 10.1182/blood-2005-09-3724. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-09-3724v1 107/9/3481    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Appelbaum, F. R. Articles by Petersdorf, S. H. Search for Related Content PubMed PubMed Citation Articles by Appelbaum, F. R. Articles by Petersdorf, S. H. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Age and acute myeloid leukemia Frederick R. Appelbaum, Holly Gundacker, David R. Head, Marilyn L. Slovak, Cheryl L. Willman, John E. Godwin, Jeanne E. Anderson, and Stephen H. Petersdorf From the Fred Hutchinson Cancer Research Center, Seattle, WA; the Southwest Oncology Group Statistical Center, Seattle, WA; the Vanderbilt University Medical Center, Nashville, TN; the City of Hope National Medical Center, Duarte, CA; the University of New Mexico, Albuquerque, NM; the Loyola University Stritch School of Medicine, Maywood, IL; the Katmai Oncology Group, Anchorage, AK; and the Seattle Cancer Care Alliance, Seattle, WA. We conducted a retrospective analysis of 968 adults with acute myeloid leukemia (AML) on 5 recent Southwest Oncology Group trials to understand how the nature of AML changes with age. Older study patients with AML presented with poorer performance status, lower white blood cell counts, and a lower percentage of marrow blasts. Multidrug resistance was found in 33% of AMLs in patients younger than age 56 compared with 57% in patients older than 75. The percentage of patients with favorable cytogenetics dropped from 17% in those younger than age 56 to 4% in those older than 75. In contrast, the proportion of patients with unfavorable cytogenetics increased from 35% in those younger than age 56 to 51% in patients older than 75. Particularly striking were the increases in abnormalities of chromosomes 5, 7, and 17 among the elderly. The increased incidence of unfavorable cytogenetics contributed to their poorer outcome, and, within each cytogenetic risk group, treatment outcome deteriorated markedly with age. Finally, the combination of a poor performance status and advanced age identified a group of patients with a very high likelihood of dying within 30 days of initiating induction therapy. The distinct biology and clinical responses seen argue for age-specific assessments when evaluating therapies for AML. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. E. Karp, K. Flatten, E. J. Feldman, J. M. Greer, D. A. Loegering, R. M. Ricklis, L. E. Morris, E. Ritchie, B. D. Smith, V. Ironside, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide Blood, May 14, 2009; 113(20): 4841 - 4852. [Abstract] [Full Text] [PDF] G. Juliusson, P. Antunovic, A. Derolf, S. Lehmann, L. Mollgard, D. Stockelberg, U. Tidefelt, A. Wahlin, and M. Hoglund Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood, April 30, 2009; 113(18): 4179 - 4187. [Abstract] [Full Text] [PDF] H. D. Klepin and L. Balducci Acute Myelogenous Leukemia in Older Adults Oncologist, March 1, 2009; 14(3): 222 - 232. [Abstract] [Full Text] [PDF] P. S. Becker, K. J. Kopecky, A. N. Wilks, S. Chien, J. M. Harlan, C. L. Willman, S. H. Petersdorf, D. L. Stirewalt, T. Papayannopoulou, and F. R. Appelbaum Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia Blood, January 22, 2009; 113(4): 866 - 874. [Abstract] [Full Text] [PDF] T. Buchner, W. E. Berdel, C. Haferlach, T. Haferlach, S. Schnittger, C. Muller-Tidow, J. Braess, K. Spiekermann, J. Kienast, P. Staib, et al. Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group J. Clin. Oncol., January 1, 2009; 27(1): 61 - 69. [Abstract] [Full Text] [PDF] B. D. Shah and J. E. Lancet Frontline Treatment of Acute Myeloid Leukemia: Are We Making Progress? ASCO Educational Book, January 1, 2009; 2009(1): 372 - 377. [Abstract] [Full Text] [PDF] G. J. Roboz Treatment of Elderly Patients with Acute Myeloid Leukemia: Lowering the Intensity ASCO Educational Book, January 1, 2009; 2009(1): 378 - 383. [Abstract] [Full Text] [PDF] M. A. Sekeres, P. Elson, M. E. Kalaycio, A. S. Advani, E. A. Copelan, S. Faderl, H. M. Kantarjian, and E. Estey Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients Blood, January 1, 2009; 113(1): 28 - 36. [Abstract] [Full Text] [PDF] J.-V. Malfuson, A. Etienne, P. Turlure, T. de Revel, X. Thomas, N. Contentin, C. Terre, S. Rigaudeau, D. Bordessoule, N. Vey, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia Haematologica, December 1, 2008; 93(12): 1806 - 1813. [Abstract] [Full Text] [PDF] H. Wandt, U. Schakel, F. Kroschinsky, G. Prange-Krex, B. Mohr, C. Thiede, U. Pascheberg, S. Soucek, M. Schaich, and G. Ehninger MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients Blood, February 15, 2008; 111(4): 1855 - 1861. [Abstract] [Full Text] [PDF] M. R. Baer, H. D. Klepin, and A. S. Artz Acute Leukemia in Older Adults: Are We Treating Too Much or Too Little? ASCO Educational Book, January 1, 2008; 2008(1): 216 - 223. [Abstract] [Full Text] [PDF] M. L. Sorror, S. Giralt, B. M. Sandmaier, M. De Lima, M. Shahjahan, D. G. Maloney, H. J. Deeg, F. R. Appelbaum, B. Storer, and R. Storb Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences Blood, December 15, 2007; 110(13): 4606 - 4613. [Abstract] [Full Text] [PDF] M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF] C. Gardin, P. Turlure, T. Fagot, X. Thomas, C. Terre, N. Contentin, E. Raffoux, S. de Botton, C. Pautas, O. Reman, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial Blood, June 15, 2007; 109(12): 5129 - 5135. [Abstract] [Full Text] [PDF] E. Estey Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1908 - 1915. [Abstract] [Full Text] [PDF] I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood, April 1, 2007; 109(7): 2781 - 2790. [Abstract] [Full Text] [PDF] F. R. Appelbaum, D. Rosenblum, R. J. Arceci, W. L. Carroll, P. P. Breitfeld, S. J. Forman, R. A. Larson, S. J. Lee, S. B. Murphy, S. O'Brien, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia Blood, March 1, 2007; 109(5): 1810 - 1816. [Abstract] [Full Text] [PDF] J. E. Lancet, I. Gojo, J. Gotlib, E. J. Feldman, J. Greer, J. L. Liesveld, L. M. Bruzek, L. Morris, Y. Park, A. A. Adjei, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia Blood, February 15, 2007; 109(4): 1387 - 1394. [Abstract] [Full Text] [PDF] H. P. Erba Prognostic Factors in Elderly Patients with AML and the Implications for Treatment Hematology, January 1, 2007; 2007(1): 420 - 428. [Abstract] [Full Text] [PDF] S. Jeha and F. J. Giles Acute myeloid leukemia ASH Self-Assessment Program, January 1, 2007; 2007(1): 243 - 252. [Full Text] [PDF] T. Buchner, W. E. Berdel, C. Schoch, T. Haferlach, H. L. Serve, J. Kienast, S. Schnittger, W. Kern, J. Tchinda, A. Reichle, et al. Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1977 - 1977. [Abstract] [PDF] M. S. Dhami, A. Bulgaru, K. Jagathambal, D. Kapur, D. E. Slater, E. G. Maderazo, and F. A. Bauer Treatment of Acute Myeloid Leukemia in a Community Hospital. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 4575 - 4575. [Abstract] [PDF] R. M. Stone Older AML patients: fit for what? Blood, November 15, 2006; 108(10): 3232 - 3233. [Full Text] [PDF] C. A. Schiffer Clinical Issues in the Management of Patients with Myelodysplasia Hematology, January 1, 2006; 2006(1): 205 - 210. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020